Follicular lymphoma (FL) is generally considered incurable due to its relapsing pattern, with shorter durations of response and progression-free survival with each subsequent therapy. As a result of this relapsing nature, management of patients with FL requires multiple lines of therapy with varied mechanisms of action—including, among others, the R2 regimen, an EZH2 inhibitor, phosphatidylinositol-3-kinase (PI3K) inhibitors, and chimeric antigen receptor (CAR) T-cell therapies. To optimize patient outcomes, it is of the utmost importance to be aware of which patient and disease characteristics to consider when sequencing such a robust range of treatment options, as well as the mechanism of action and adverse events associated with each agent. In this interactive video lecture, an expert discusses management strategies for patients with FL through the lens of clinical trial data along with real-world anecdotes.
Interactive video lecture
After completing this activity, participants should be better able to:
- Identify appropriate treatment strategies in patients with relapsed/refractory (RR) FL based on relevant clinical trial data and approved indications
- Implement strategies to identify, monitor, and manage treatment-related adverse events in patients with RRFL
- Use resources and strategies to educate patients with RRFL and their caregivers on toxicity management and adherence to treatment
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 16, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from Astellas and Pﬁzer; AstraZeneca; Bristol-Myers Squibb; Dendreon Pharmaceuticals LLC; Eisai; Epizyme Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Regeneron Pharmaceuticals, Inc. and Sanoﬁ Genzyme; and Seagen Inc. formerly Seattle Genetics.
This activity is supported by an educational grant from Bristol-Myers Squibb and Epizyme Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Burke: consulting: AbbVie, Adaptive Biotherapeutics, AstraZeneca, Bayer Healthcare, Epizyme, Genentech/Roche, Kura Oncology, Kymera Therapeutics, MorphoSys, Novartis, Verastem Oncology; consulting/speakers bureau: Beigene, Seagen.
Ms Sandy: speakers bureau: AstraZeneca, Jazz, Merck, Takeda.
Ms Williams: consulting/speakers bureau: AbbVie, AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 17, 2021
Expiration date: August 16, 2022
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 100621O-7D